PROCRIT® (epoetin alfa)
(epoetin alfa)
AXERT® (almotriptan malate) Tablets
CONCERTA® (methylphenidate HCI) Extended-Release Tablets CII
DITROPAN XL® (oxybutynin chloride)
DITROPAN XL®
DOXIL® (doxorubicin HCl liposome injection)
DURAGESIC® (fentanyl transdermal system) CII
EDURANT® (rilpivirine)
ELMIRON® (pentosan polysulfate sodium) Capsules
HALDOL® (haloperidol)
HALDOL® DECANOATE (haloperidol)
HALDOL® DECANOATE
INTELENCE® (etravirine)
INVEGA® (paliperidone)
INVEGA SUSTENNA® (paliperidone palmitate)
INVEGA SUSTENNA®
INVOKAMET™ (canagliflozin/metformin HCl) tablets
INVOKANA® (canagliflozin)
LEVAQUIN® (levofloxacin) Tablets
NUCYNTA® (tapentadol)
NUCYNTA® ER (tapentadol extended-release tablets)
NUCYNTA® ER
OLYSIO® (simeprevir)
ONETOUCH® Meters and Test Strips
ORTHO TRI-CYCLEN® LO (norgestimate/ethinyl estradiol)
ORTHO TRI-CYCLEN® LO
PANCREAZE® (pancrelipase) Delayed-Release Capsules
PARAFON FORTE® DSC (chlorzoxazone)
PARAFON FORTE® DSC
PREZISTA® (darunavir) Tablets
PROCRIT® (epoetin alfa)
RAZADYNE® (galantamine)
RAZADYNE® ER (galantamine HBr) Extended-Release Capsules
RAZADYNE® ER
REMICADE® (infliximab)
RISPERDAL® (risperidone)
RISPERDAL CONSTA® (risperidone)
RISPERDAL CONSTA®
SIMPONI® (golimumab)
SIMPONI ARIA® (golimumab) for infusion
SIMPONI ARIA®
SPORANOX® (itraconazole)
STELARA® (ustekinumab)
SYLVANT™ (siltuximab)
TERAZOL® (terconazole)
TOPAMAX® (topiramate) Tablets
ULTRACET® (tramadol hydrochloride/acetaminophen)
ULTRAM® (tramadol hydrochloride)
ULTRAM® ER (tramadol HCI) Extended-Release Tablets
ULTRAM® ER
XARELTO® (rivaroxaban)
ZYTIGA® (abiraterone acetate)

Need help paying for your PROCRIT® (epoetin alfa) prescription?

We want to guide you to programs that may help. Here you'll find the financial assistance programs available for PROCRIT®. We have also listed most of the eligibility requirements for each so you can narrow your focus to those that best suit your circumstances. Call the programs or visit their web sites to learn more.

PROCRITline®

1-800-553-3851

Monday-Friday, 8 AM to 8 PM ET

To view programs that are best suited for you, select your insurance status for PROCRIT® or view all assistance programs

You may be eligible for one or more of the following programs:

To view programs that are best suited for you, select your insurance status for PROCRIT® or view all assistance programs

You may be eligible for one or more of the following programs:

At the current time, patient affordability programs for the selected insurance option are not available for this product. Please check back, as programs change.

The following programs are not affiliated with Janssen.

Be sure to contact the programs directly to get details on eligibility and application requirements, and to see if they have funding available to help you.

Johnson & Johnson Patient Assistance Foundation

Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) is committed to providing access to medicines for uninsured patients who lack the financial resources to pay for them. If you need PROCRIT® (epoetin alfa), and are uninsured and unable to pay for your medicine, please contact a JJPAF program specialist at 1-800-652-6227 9 AM to 6 PM ET or visit the foundation website at JJPAF.org to see if you might qualify for assistance.

State-Sponsored Programs

Some states sponsor prescription financial assistance programs, each with its own eligibility requirements.

Find out if your state has a program that can help you »

Medicare Savings Program

Many states have programs for people with limited income and resources that pay some or all of Medicare's premiums and may pay Medicare deductibles and co-insurance. Find out if your state has a program that can help you.

Medicare Part D Extra Help — Low-Income Subsidy

Medicare patients who have limited income and resources may qualify for "extra help" to pay for prescription drugs. The Low-Income Subsidy (LIS) program from Medicare provides financial assistance for patients who may otherwise be unable to afford the costs associated with their Medicare Part D plan.

Those who are eligible for LIS may:

  • Receive assistance paying their monthly premium
  • Have a reduced or no deductible
  • Have reduced or no prescription co-insurance and co-payments
  • Have no gap in coverage

Patient Advocate Foundation

This foundation provides financial assistance to those eligible for their out-of-pocket medication expenses.

This foundation may be able to help you if:

  • You have private/commercial or government insurance coverage for PROCRIT®
    AND
  • You are taking PROCRIT® to treat Chemotherapy-Induced Anemia

The HealthWell Foundation®

This foundation provides financial assistance to those eligible for co-insurance, co-payments, healthcare premiums and deductibles for certain medications.

This foundation may be able to help you if:

  • You have private/commercial or government insurance coverage for PROCRIT®
    AND
  • You are taking PROCRIT® to treat Anemia in Chronic Renal Insufficiency or CRF, Chemotherapy-Induced Anemia
January 20, 2015
Expand
Expand

IMPORTANT SAFETY INFORMATION

INDICATIONS

Anemia Due to Chronic Kidney Disease

PROCRIT® is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and not on dialysis to decrease the need for red blood cell (RBC) transfusion.

Anemia Due to Zidovudine in HIV-infected Patients

PROCRIT® is indicated for the treatment of anemia due to zidovudine administered at ≤ 4200 mg/week in HIV-infected patients with endogenous serum erythropoietin levels of ≤ 500 mUnits/mL.

Anemia Due to Chemotherapy in Patients With Cancer

PROCRIT® is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.

Reduction of Allogeneic Red Blood Cell Transfusions in Patients Undergoing Elective, Noncardiac, Nonvascular Surgery

PROCRIT® is indicated to reduce the need for allogeneic RBC transfusions among patients with perioperative hemoglobin > 10 to ≤ 13 g/dL who are at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery. PROCRIT® is not indicated for patients who are willing to donate autologous blood preoperatively.

PROCRIT® has not been shown to improve quality of life, fatigue, or patient well-being.

PROCRIT® is not indicated for use:

  • In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy.
  • In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure.
  • In patients scheduled for surgery who are willing to donate autologous blood.
  • In patients undergoing cardiac or vascular surgery.
  • As a substitute for RBC transfusions in patients who require immediate correction of anemia.

WARNINGS: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE

Chronic Kidney Disease:

  • In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL.
  • No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks.
  • Use the lowest PROCRIT® dose sufficient to reduce the need for red blood cell (RBC) transfusions.

Cancer:

  • ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers.
  • Because of these risks, prescribers and hospitals must enroll in and comply with the ESA APPRISE Oncology program to prescribe and/or dispense PROCRIT® to patients with cancer. To enroll in the ESA APPRISE Oncology Program, visit www.esa-apprise.com or call 1-866-284-8089 for further assistance.
  • To decrease these risks, as well as the risk of serious cardiovascular and thromboembolic reactions, use the lowest dose needed to avoid red blood cell (RBC) transfusions.
  • Use ESAs only for anemia from myelosuppressive chemotherapy.
  • ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure.
  • Discontinue following the completion of a chemotherapy course.

Perisurgery:  Due to increased risk of deep venous thrombosis (DVT), DVT prophylaxis is recommended.

(See WARNINGS AND PRECAUTIONS: Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism, WARNINGS AND PRECAUTIONS: Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence in Patients With Cancer, INDICATIONS AND USAGE, and DOSAGE AND ADMINISTRATION.)

Contraindications

PROCRIT® is contraindicated in patients with:

PROCRIT® from multidose vials contains benzyl alcohol and is contraindicated in:

Additional Important Safety Information

Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism

Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence in Patients With Cancer

Hypertension

Seizures

Lack or Loss of Hemoglobin Response to PROCRIT®

Pure Red Cell Aplasia

Serious Allergic Reactions

Laboratory Monitoring

PROCRIT® is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.

Anemia in Patients with Chronic Kidney Disease Not on Dialysis

Chemotherapy-Induced Anemia

Surgery/Perisurgery

Anemia in Zidovudine-treated HIV-infected Patients

These are not all of the possible side effects of PROCRIT®. Your healthcare provider can give you a more complete list. Tell your healthcare provider about any side effects that bother you or that do not go away.

For medication information inquiries or to report adverse events or product quality complaints related to our products, please contact the Janssen Medical Information at 1-800-JANSSEN (1-800-526-7736) (9:00 AM - 5:00 PM ET, Monday through Friday) or http://www.janssenmedicalinformation.com/.

Please see full Prescribing Information, including Boxed WARNING. Please read the Medication Guide and discuss with your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088 (1-800-332-1088).

08P11013F

IMPORTANT SAFETY INFORMATION

INDICATIONS

Anemia Due to Chronic Kidney Disease

PROCRIT® is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and not on dialysis to decrease the need for red blood cell (RBC) transfusion.

Anemia Due to Zidovudine in HIV-infected Patients

PROCRIT® is indicated for the treatment of anemia due to zidovudine administered at ≤ 4200 mg/week in HIV-infected patients with endogenous serum erythropoietin levels of ≤ 500 mUnits/mL.

Anemia Due to Chemotherapy in Patients With Cancer

PROCRIT® is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.

Reduction of Allogeneic Red Blood Cell Transfusions in Patients Undergoing Elective, Noncardiac, Nonvascular Surgery

PROCRIT® is indicated to reduce the need for allogeneic RBC transfusions among patients with perioperative hemoglobin > 10 to ≤ 13 g/dL who are at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery. PROCRIT® is not indicated for patients who are willing to donate autologous blood preoperatively.

PROCRIT® has not been shown to improve quality of life, fatigue, or patient well-being.

PROCRIT® is not indicated for use:

  • In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy.
  • In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure.
  • In patients scheduled for surgery who are willing to donate autologous blood.
  • In patients undergoing cardiac or vascular surgery.
  • As a substitute for RBC transfusions in patients who require immediate correction of anemia.

WARNINGS: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE

Chronic Kidney Disease:

  • In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL.
  • No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks.
  • Use the lowest PROCRIT® dose sufficient to reduce the need for red blood cell (RBC) transfusions.

Cancer:

  • ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers.
  • Because of these risks, prescribers and hospitals must enroll in and comply with the ESA APPRISE Oncology program to prescribe and/or dispense PROCRIT® to patients with cancer. To enroll in the ESA APPRISE Oncology Program, visit www.esa-apprise.com or call 1-866-284-8089 for further assistance.
  • To decrease these risks, as well as the risk of serious cardiovascular and thromboembolic reactions, use the lowest dose needed to avoid red blood cell (RBC) transfusions.
  • Use ESAs only for anemia from myelosuppressive chemotherapy.
  • ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure.
  • Discontinue following the completion of a chemotherapy course.

Perisurgery:  Due to increased risk of deep venous thrombosis (DVT), DVT prophylaxis is recommended.

(See WARNINGS AND PRECAUTIONS: Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism, WARNINGS AND PRECAUTIONS: Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence in Patients With Cancer, INDICATIONS AND USAGE, and DOSAGE AND ADMINISTRATION.)

Contraindications

PROCRIT® is contraindicated in patients with:

PROCRIT® from multidose vials contains benzyl alcohol and is contraindicated in:

Additional Important Safety Information

Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism

Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence in Patients With Cancer

Hypertension

Seizures

Lack or Loss of Hemoglobin Response to PROCRIT®

Pure Red Cell Aplasia

Serious Allergic Reactions

Laboratory Monitoring

PROCRIT® is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.

Anemia in Patients with Chronic Kidney Disease Not on Dialysis

Chemotherapy-Induced Anemia

Surgery/Perisurgery

Anemia in Zidovudine-treated HIV-infected Patients

These are not all of the possible side effects of PROCRIT®. Your healthcare provider can give you a more complete list. Tell your healthcare provider about any side effects that bother you or that do not go away.

For medication information inquiries or to report adverse events or product quality complaints related to our products, please contact the Janssen Medical Information at 1-800-JANSSEN (1-800-526-7736) (9:00 AM - 5:00 PM ET, Monday through Friday) or http://www.janssenmedicalinformation.com/.

Please see full Prescribing Information, including Boxed WARNING. Please read the Medication Guide and discuss with your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088 (1-800-332-1088).

08P11013F